James Rolke
Chief Executive Officer presso REVELATION BIOSCIENCES, INC.
Patrimonio netto: 1 858 $ in data 31/03/2024
Profilo
James M.
Rolke is currently the Chief Executive Officer & Director at Revelation Biosciences Sub, Inc. and Revelation Biosciences, Inc. He is also a Director at Revelation Therapeutics LLC.
Previously, he held positions such as Associate Director-Pharmaceutical Development at Mersana Therapeutics, Operations Director at Prospect Therapeutics, Chief Scientific Officer at La Jolla Pharmaceutical Co., Manager-Process Development at Glycogenesys, and Chief Technology Officer at Pluromed, Inc. He also worked as an Associate Scientist at Alpha-Beta Technology, Inc., Principal Scientist at Surgical Sealants, Inc., and Scientist at Geltex, Inc. Mr. Rolke received his undergraduate degree from Keene State College.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 18/03/2024 | 678 ( 0.04% ) | 1 858 $ | 31/03/2024 |
Posizioni attive di James Rolke
| Società | Posizione | Inizio |
|---|---|---|
| REVELATION BIOSCIENCES, INC. | Chief Executive Officer | 01/05/2020 |
Revelation Therapeutics LLC
 Revelation Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Revelation Therapeutics LLC provides biotechnology services. The company is headquartered in Menlo Park, CA. | Director/Board Member | - |
Revelation Biosciences Sub, Inc.
 Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The private company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | Chief Executive Officer | 01/05/2020 |
Precedenti posizioni note di James Rolke
| Società | Posizione | Fine |
|---|---|---|
| LA JOLLA PHARMACEUTICAL COMPANY | Chief Tech/Sci/R&D Officer | 31/05/2020 |
Pluromed, Inc.
 Pluromed, Inc. Medical SpecialtiesHealth Technology Pluromed, Inc. manufactures and markets disposable medical devices that are used to control bleeding during surgery. The company's trademark products include LeGoo Internal Vessel Occluder and BackStop. It was founded in 2003 and is located in Woburn, MA. | Chief Tech/Sci/R&D Officer | 01/01/2012 |
Prospect Therapeutics, Inc.
 Prospect Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Prospect Therapeutics, Inc. develops biopharmaceuticals to treat variety of cancers. The firm's products include GCS-100, for the treatment of leukemia, multiple myeloma and lymphoma, GCS-100, a proprietary polysaccharide, targets galectin-3, a protein over-expressed in cancer cells that promotes their survival, proliferation and metastasis. The company was founded by Joseph Grimm, George Tidmarsh, and Kevin Tang in July 2006 and is headquartered in Woburn, MA. | Corporate Officer/Principal | 01/01/2009 |
| MERSANA THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2007 |
Glycogenesys, Inc.
 Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01/01/2006 |
Formazione di James Rolke
| Keene State College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| MERSANA THERAPEUTICS, INC. | Health Technology |
| REVELATION BIOSCIENCES, INC. | Health Technology |
| Aziende private | 9 |
|---|---|
Alpha-Beta Technology, Inc.
 Alpha-Beta Technology, Inc. Electronic ComponentsElectronic Technology Alpha-Beta Technology, Inc. engages in the discovery, development and commercialization of novel carbohydrate-based products for the prevention and treatment of infectious disease. It develops a novel class of immune modulation pharmaceutical products composed of complex carbohydrates and is discovering and developing new anti-fungal diagnostics and drugs. In addition, Alpha-Beta has developed a rapid in vitro diagnostic to detect and monitor systemic fungal infections and has an anti-fungal research program to discover direct inhibitors of fungal cell wall synthesis. It is in the development stage and is devoting substantially all of its efforts toward product research and development, raising capital, marketing products under development, clinical trials and manufacturing. The Company was founded on March 2, 1988 and is headquartered in Worcester, MA. | Electronic Technology |
La Jolla Pharmaceutical Co.
 La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. | Health Technology |
Glycogenesys, Inc.
Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | Commercial Services |
Pluromed, Inc.
Pluromed, Inc. Medical SpecialtiesHealth Technology Pluromed, Inc. manufactures and markets disposable medical devices that are used to control bleeding during surgery. The company's trademark products include LeGoo Internal Vessel Occluder and BackStop. It was founded in 2003 and is located in Woburn, MA. | Health Technology |
Prospect Therapeutics, Inc.
Prospect Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Prospect Therapeutics, Inc. develops biopharmaceuticals to treat variety of cancers. The firm's products include GCS-100, for the treatment of leukemia, multiple myeloma and lymphoma, GCS-100, a proprietary polysaccharide, targets galectin-3, a protein over-expressed in cancer cells that promotes their survival, proliferation and metastasis. The company was founded by Joseph Grimm, George Tidmarsh, and Kevin Tang in July 2006 and is headquartered in Woburn, MA. | Health Technology |
| Surgical Sealants, Inc. | |
Revelation Therapeutics LLC
Revelation Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services Revelation Therapeutics LLC provides biotechnology services. The company is headquartered in Menlo Park, CA. | Commercial Services |
Revelation Biosciences Sub, Inc.
Revelation Biosciences Sub, Inc. Medical SpecialtiesHealth Technology Part of Revelation Biosciences, Inc., Revelation Biosciences Sub, Inc. develops medical devices. The private company is based in San Diego, CA. James M. Rolke has been the CEO of the company since 2020. Revelation Biosciences Sub was acquired by Petra Acquisition, Inc. on January 11, 2022 for $87.36 million. | Health Technology |
| Geltex, Inc. |
- Borsa valori
- Insiders
- James Rolke
